- €685.84m
- €647.10m
- $376.13m
Brief: Pharming Group H1 Operating Profit USD -3.6 Million
Pharming shares plunge on declining Ruconest sales
Netherlands' Pharming Group prelim Q1 revenue falls on lower RUCONEST sales
Brief: Pharming Group Q1 Net Income USD -5.2 Million
Brief: EMA's CHMP Recommends Extension Of Therapeutic Indication For Pfizer's Hympavzi
Brief: Pharming Group NV Receives Positive CHMP Opinion for Joenja
Brief: Pharming Group Annouces Approval of Activated Phosphoinositide 3-Kinase Delta Syndrome Treatment In Japan
Brief: Pharming Group Eyes 2026 Total Revenues Between $405-425 MILLION
Netherlands' Pharming 2025 revenue rises on higher volumes, pricing
Pharming jumps after upbeat revenue guidance for 2026
Brief: Pharming Group Expects 2026 Revenue At $405-$425 Mln
Brief: Pharming Group Says Co Receives Complete Response Letter From U.S. FDA For SNDA For Joenja (Leniolisib) In Children Aged 4 To 11 Years With Apds
Pharming shares rise 5% as 2025 preliminary revenue exceeds guidance
Brief: Pharming Group Projects 2025 Revenues Of $376 Mln, Ahead Of Guidance
Brief: Pharming Group Hikes FY Revenue Guidance To $365-375 Mln
Brief: Pharming Group 9M Operating Profit USD 19.6 Million
Brief: Pharming Group Anticipates $7 Mln Restructuring Costs In Q4
FDA Acceptance, Priority Review For Leniolisib In Children With APDS
Brief: Euronext Expands Amsterdam's AEX Index To 30 Constituents As Of Sept. 22